{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:30:48Z","timestamp":1789767048093,"version":"4.0.1"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejmech.2020.112862","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T11:05:18Z","timestamp":1600513518000},"page":"112862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Primed for global coronavirus pandemic: Emerging research and clinical outcome"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-7806","authenticated-orcid":false,"given":"Shakir","family":"Ahamad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scotty","family":"Branch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3478-6999","authenticated-orcid":false,"given":"Shea","family":"Harrelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2915-8106","authenticated-orcid":false,"given":"Mohd Kamil","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Saquib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112862_bib1","article-title":"The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","author":"Gorbalenya","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2020.112862_bib2","article-title":"Will novel virus go pandemic or be contained?","author":"Kupferschmidt","year":"2020","journal-title":"Science (80)"},{"key":"10.1016\/j.ejmech.2020.112862_bib3","doi-asserted-by":"crossref","DOI":"10.3201\/eid1209.05-0979","article-title":"Influenza: the mother of all pandemics","author":"Taubenberger","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112862_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2951-z","article-title":"A\u00a0pneumonia outbreak associated with a new coronavirus of probable bat origin","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112862_bib5","series-title":"Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)","author":"Johns Hopkins Hospital and Medicine","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/vex012","article-title":"Global patterns in coronavirus diversity","author":"Anthony","year":"2017","journal-title":"Virus Evol"},{"key":"10.1016\/j.ejmech.2020.112862_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ejmech.2020.112862_bib8","series-title":"How Did Coronavirus Start and where Did it Come from? Was it Really Wuhan\u2019s Animal Market?","author":"Readfearn","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib9","article-title":"Mystery deepens over animal source of coronavirus","author":"Cyranoski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112862_bib10","article-title":"An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov)","author":"Tang","year":"2020","journal-title":"Infect. Dis. Model."},{"key":"10.1016\/j.ejmech.2020.112862_bib11","series-title":"Covid-19: One Third of Humanity under Virus Lockdown","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib12","article-title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)","author":"Shanmugaraj","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.ejmech.2020.112862_bib13","series-title":"In: StatPearls","article-title":"Features, evaluation and treatment coronavirus (COVID-19)","author":"Cascella","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib14","series-title":"Coronaviruses Methods Protoc","first-page":"1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","author":"Fehr","year":"2015"},{"key":"10.1016\/j.ejmech.2020.112862_bib15","series-title":"Q&A on Coronaviruses (COVID-19)","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","author":"Morse","year":"2020","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2020.112862_bib17","series-title":"Landscape Analysis of Therapeutics as March 21 2020","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib18","series-title":"Draft Landscape of COVID-19 Candidate Vaccines","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/phar.2398","article-title":"Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019","author":"Barlow","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejmech.2020.112862_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2020.03.006","article-title":"Ongoing clinical trials for the management of the COVID-19 pandemic","author":"Lythgoe","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2020.112862_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","author":"Sanders","year":"2020","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.ejmech.2020.112862_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/S2589-7500(20)30086-8","article-title":"A\u00a0real-time dashboard of clinical trials for COVID-19","author":"Thorlund","year":"2020","journal-title":"Lancet Digit. Heal."},{"key":"10.1016\/j.ejmech.2020.112862_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072657","article-title":"A\u00a0review of sars-cov-2 and the ongoing clinical trials","author":"Tu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2020.112862_bib24","article-title":"Clinical trials for the prevention and treatment of coronavirus disease 2019 (COVID-19): the current state of play","author":"Davis Js","year":"2020","journal-title":"Med. J. Aust. \u2013 Prepr."},{"key":"10.1016\/j.ejmech.2020.112862_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.00658","article-title":"The current and future state of vaccines, antivirals and gene therapies against emerging coronaviruses","author":"Tse","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2020.112862_bib26","series-title":"Moderna Ships mRNA Vaccine against Novel Coronavirus (mRNA-1273) for Phase 1 Study","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib27","series-title":"Moderna\u2019s Phase I Covid-19 mRNA Vaccine Has Manufacturing Edge but Many Obstacles to Confirm Protection Lay Ahead","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib28","series-title":"Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) against Novel Coronavirus","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib29","series-title":"Moderna Receives FDA Fast Track Designation for mRNA Vaccine (mRNA-1273) against Novel Coronavirus","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib30","series-title":"Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) against Novel Coronavirus","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib31","series-title":"CanSinoBIO\u2019s Investigational Vaccine against COVID-19 Approved for Phase 1 Clinical Trial in China","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib32","series-title":"China\u2019s CanSino Prepares to Advance COVID-19 Vaccine Candidate into Phase II","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib33","series-title":"CanSino Bio Enrols for Ph 2 Trial of COVID-19 Vaccine","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib34","series-title":"Oxford COVID-19 Vaccine to Begin Phase II\/III Human Trials","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib35","series-title":"INO-4800 DNA Coronavirus Vaccine, Precis. Vacciniation","author":"Carlson","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib36","series-title":"IVI and SNU Partner to Trial Inovio\u2019s Covid-19 Vaccine in Korea","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib37","series-title":"Novavax Initiates Phase 1\/2 Clinical Trial of COVID-19 Vaccine","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib38","series-title":"Sinovac Announces Positive Preliminary Results of Phase I\/II Clinical Trials for Inactivated Vaccine Candidate against COVID-19","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.112862_bib40","series-title":"Therapeutic Drug Repurposing, Repositioning and Rescue: Part II: Business Review","author":"Naylor","year":"2015"},{"key":"10.1016\/j.ejmech.2020.112862_bib41","doi-asserted-by":"crossref","DOI":"10.4155\/fdd-2020-0010","article-title":"Drug repurposing strategies for COVID-19","author":"Senanayake","year":"2020","journal-title":"Futur. Drug Discov"},{"key":"10.1016\/j.ejmech.2020.112862_bib42","doi-asserted-by":"crossref","DOI":"10.1007\/s12250-020-00204-7","article-title":"Old weapon for new enemy: drug repurposing for treatment of newly emerging viral diseases","author":"Guo","year":"2020","journal-title":"Virol. Sin."},{"key":"10.1016\/j.ejmech.2020.112862_bib43","article-title":"Drug repurposing: progress, challenges and recommendations","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112862_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105955","article-title":"The epidemiology, diagnosis and treatment of COVID-19","author":"Zhai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2020.112862_bib45","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A\u00a0trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","author":"Cao","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.112862_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2020.112862_bib47","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol","author":"Kadam","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2020.112862_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112862_bib49","series-title":"The Efficacy of Lopinavir Plus Ritonavir and Arbidol against Novel Coronavirus Infection","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib50","article-title":"Efficacy and safety of lopinavir\/ritonavir or arbidol in adult patients with mild\/moderate COVID-19: an exploratory randomized controlled trial","author":"Li","year":"2020","journal-title":"Med"},{"key":"10.1016\/j.ejmech.2020.112862_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2020.05.085","article-title":"Lack of antiviral activity of darunavir against SARS-CoV-2","author":"De Meyer","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112862_bib52","series-title":"J&J Says No Evidence Darunavir Works against Coronavirus","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib53","series-title":"Clinical Study for Safety and Efficacy of Favipiravir in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib54","article-title":"More than 80 clinical trials launch to test coronavirus treatments","author":"Maxmen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112862_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.ejmech.2020.112862_bib56","series-title":"Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial","author":"Chen","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib57","series-title":"Russia\u2019s ChemRar Reports Positive Data of Favipiravir in Covid-19","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib58","series-title":"WHO Director-General\u2019s Opening Remarks at the Media Briefing on COVID-19 - 18 March 2020","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.3204","article-title":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore","author":"Young","year":"2020","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.ejmech.2020.112862_bib60","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu C M","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.ejmech.2020.112862_bib61","series-title":"The Hydroxychloroquine Debate Continues","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib62","article-title":"A\u00a0systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","author":"Cortegiani","year":"2020","journal-title":"J.\u00a0Crit. Care"},{"key":"10.1016\/j.ejmech.2020.112862_bib63","series-title":"Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2020.112862_bib65","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in\u00a0vitro","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2020.112862_bib66","first-page":"215","article-title":"A\u00a0pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19","volume":"49","author":"Chen","year":"2020","journal-title":"J.\u00a0Zhejiang Univ."},{"key":"10.1016\/j.ejmech.2020.112862_bib67","series-title":"Efficacy of Hydroxychloroquine in Patients with COVID-19: Results of a Randomized Clinical Trial","author":"Chen","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2020.06.001","article-title":"Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19","author":"Magagnoli","year":"2020","journal-title":"Med"},{"key":"10.1016\/j.ejmech.2020.112862_bib69","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with covid-19","author":"Geleris","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.112862_bib70","series-title":"Q&A\u00a0: Hydroxychloroquine and COVID-19","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib71","series-title":"Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","author":"Jordheim","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112862_bib73","article-title":"Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment","year":"2020","journal-title":"Stat"},{"key":"10.1016\/j.ejmech.2020.112862_bib74","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 \u2014 preliminary report","author":"Beigel","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.112862_bib75","series-title":"Gilead Announces Results from Phase 3 Trial of Investigational Antiviral Remdesivir in Patients with Severe COVID-19","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib76","series-title":"Gilead\u2019s Suspension of Covid-19 Trials in China Should Serve as a Bellwether for Studies in Other Countries","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib77","series-title":"Montefiore and Einstein Assess Remdesivir and Baricitinib for Covid-19","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib78","series-title":"Global Coronavirus COVID-19 Clinical Trial Tracker","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2020.05.018","article-title":"Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies","author":"Singh","year":"2020","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"10.1016\/j.ejmech.2020.112862_bib80","series-title":"Recovery: Randomized Evaluation of COVID-19 Therapy","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib81","series-title":"COVID-19 Treatments Could Be Fast-Tracked through New National Clinical Trial Initiative","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib82","series-title":"Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report","author":"Horby","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib83","series-title":"WHO Director-General\u2019s Opening Remarks at the Media Briefing on COVID-19.","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib84","doi-asserted-by":"crossref","first-page":"m2512","DOI":"10.1136\/bmj.m2512","article-title":"Covid-19: demand for dexamethasone surges as RECOVERY trial publishes preprint","volume":"369","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ejmech.2020.112862_bib85","series-title":"World First Coronavirus Treatment Approved for NHS Use by Government","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib86","series-title":"Coronavirus | Government Approves Use of Dexamethasone, the Hindu","author":"Perappadan","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib87","series-title":"BerGenBio Starts Bemcentinib Dosing in ACCORD Trial","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib88","series-title":"Major COVID-19 Drugs Trial Begins in Birmingham","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib89","series-title":"Namilumab and Infliximab Selected for CATALYST Trial in UK","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102129","article-title":"Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis","author":"Muehler","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.ejmech.2020.112862_bib91","series-title":"COVID-19 Patients","article-title":"Receives first regulatory approval from German health authority BfArM to initiate a phase 2 clinical trial of its selective oral DHODH inhibitor, IMU-838","author":"Immunic, Inc","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib92","series-title":"Germany\u2019s BfArM Approves Covid-19 Trial by Immunic","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib93","series-title":"Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19, BioSpace","author":"Immunic, Inc","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib94","series-title":"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (ACOVACT)","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib95","article-title":"A\u00a0human monoclonal antibody blocking SARS-CoV-2 infection","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2020.112862_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","author":"Wrapp","year":"2020","journal-title":"Science (80)"},{"key":"10.1016\/j.ejmech.2020.112862_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.11.032","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2020.112862_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected receptor functional mimicry elucidates activation of coronavirus fusion","author":"Walls","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2020.112862_bib99","series-title":"Roche Initiates Phase III Clinical Trial of Actemra\/RoActemra Plus Remdesivir in Hospitalised Patients with Severe COVID-19 Pneumonia","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib100","series-title":"Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients with Severe COVID-19 Pneumonia","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib101","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","author":"Xu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2020.112862_bib102","series-title":"Actemra Use in Coronavirus Disease 2019 (COVID-19)","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib103","series-title":"Meplazumab Treats COVID-19 Pneumonia: an Open-Labelled, Concurrent Controlled Add-On Clinical Trial","author":"Bian","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib104","series-title":"First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia","author":"Temesgen","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib105","article-title":"A\u00a0novel protein drug, novaferon, as the potential","author":"Zheng","year":"2020","journal-title":"Antiviral Drug for COVID-19"},{"key":"10.1016\/j.ejmech.2020.112862_bib106","series-title":"aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Following FDA Acceptance of IND Application","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib107","article-title":"How blood from coronavirus survivors might save lives","author":"Maxmen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112862_bib108","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","author":"Casadevall","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2020.112862_bib109","series-title":"US Study Finds Convalescent Plasma Safe for Covid-19 Patients","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib110","series-title":"Trials of Mw Vaccine for Treatment of Covid-19 Patients to Be Initiated Soon: PGIMER Chandigarh, India Today","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib111","doi-asserted-by":"crossref","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","author":"Dong","year":"2020","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.ejmech.2020.112862_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2020.112862_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2020.112862_bib114","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.0c00052","article-title":"Broad spectrum antiviral agent niclosamide and its therapeutic potential","author":"Xu","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112862_bib115","doi-asserted-by":"crossref","DOI":"10.1021\/jm070295s","article-title":"Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus","author":"Wen","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112862_bib116","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13659-4","article-title":"SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection","author":"Gassen","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2020.112862_bib117","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs, Antimicrob","author":"Jeon","year":"2020","journal-title":"Agents Chemother"},{"key":"10.1016\/j.ejmech.2020.112862_bib118","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.48.7.2693-2696.2004","article-title":"Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide","author":"Wu","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112862_bib119","article-title":"Tilorone: a broad-spectrum antiviral invented in the USA and commercialized in Russia and beyond","author":"Ekins","year":"2020","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejmech.2020.112862_bib120","article-title":"HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV","author":"Milewska","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.ejmech.2020.112862_bib121","article-title":"SARS-CoV-2 infected host cell proteomics reveal potential therapy targets","author":"Bojkova","year":"2020","journal-title":"Res. Sq."},{"key":"10.1016\/j.ejmech.2020.112862_bib122","series-title":"Background and Scientific Rationale for Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment","author":"Brilacidin","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib123","series-title":"Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib124","series-title":"Teicoplanin Potently Blocks the Cell Entry of 2019-nCoV","author":"Zhang","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112862_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105944","article-title":"Teicoplanin: an alternative drug for the treatment of COVID-19?","author":"Baron","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2020.112862_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2020.02.018","article-title":"Discovery and development of safe-in-man broad-spectrum antiviral agents","author":"Andersen","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112862_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in\u00a0vitro","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2020.112862_bib128","doi-asserted-by":"crossref","DOI":"10.1007\/s40268-015-0083-y","article-title":"Auranofin: repurposing an old drug for a golden new age","author":"Roder","year":"2015","journal-title":"Drugs R"},{"key":"10.1016\/j.ejmech.2020.112862_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2020.05.002","article-title":"The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells","author":"Rothan","year":"2020","journal-title":"Virology"},{"key":"10.1016\/j.ejmech.2020.112862_bib130","article-title":"Drug evaluation: apilimod, an oral IL-12\/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency","author":"Billich","year":"2007","journal-title":"Idrugs"},{"key":"10.1016\/j.ejmech.2020.112862_bib131","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","author":"Ou","year":"2020","journal-title":"Nat. Commun."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420308345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420308345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:19:46Z","timestamp":1759328386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420308345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":131,"alternative-id":["S0223523420308345"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112862","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primed for global coronavirus pandemic: Emerging research and clinical outcome","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112862"}}